

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2019 September 7; 25(33): 4796-5016



**EDITORIAL**

- 4796** Role of NLRP3 inflammasome in inflammatory bowel diseases  
*Tourkochristou E, Aggeletopoulou I, Konstantakis C, Triantos C*

**OPINION REVIEW**

- 4805** Gastroesophageal reflux disease, obesity and laparoscopic sleeve gastrectomy: The burning questions  
*Bou Daher H, Sharara AI*

**REVIEW**

- 4814** Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation  
*Nicoletti A, Ponziani FR, Biolato M, Valenza V, Marrone G, Sganga G, Gasbarrini A, Miele L, Grieco A*
- 4835** Crosstalk network among multiple inflammatory mediators in liver fibrosis  
*Zhangdi HJ, Su SB, Wang F, Liang ZY, Yan YD, Qin SY, Jiang HX*

**MINIREVIEWS**

- 4850** Neoadjuvant radiotherapy for rectal cancer management  
*Feeney G, Sehgal R, Sheehan M, Hogan A, Regan M, Joyce M, Kerin M*
- 4870** *Helicobacter pylori* virulence genes  
*Šterbenc A, Jarc E, Poljak M, Homan M*
- 4885** Occupational exposure to vinyl chloride and liver diseases  
*Fedeli U, Girardi P, Mastrangelo G*

**ORIGINAL ARTICLE****Basic Study**

- 4892** *Ex vivo* effect of vascular wall stromal cells secretome on enteric ganglia  
*Dothel G, Bernardini C, Zannoni A, Spirito MR, Salaroli R, Bacci ML, Forni M, Ponti FD*
- 4904** Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source  
*Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrenner P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH*
- 4921** Identification of hepatitis B virus and liver cancer bridge molecules based on functional module network  
*Huang XB, He YG, Zheng L, Feng H, Li YM, Li HY, Yang FX, Li J*

**Retrospective Cohort Study**

- 4933** Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis  
*De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC*
- 4945** Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer  
*Cai D, Huang ZH, Yu HC, Wang XL, Bai LL, Tang GN, Peng SY, Li YJ, Huang MJ, Cao GW, Wang JP, Luo YX*

**Retrospective Study**

- 4959** Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis  
*Lee JJ, Lee HW, Lee KS*
- 4970** Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer  
*Chen XQ, Xue CR, Hou P, Lin BQ, Zhang JR*

**Observational Study**

- 4985** Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations  
*Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ*

**META-ANALYSIS**

- 4999** Efficacy of *Lactobacillus rhamnosus* GG in treatment of acute pediatric diarrhea: A systematic review with meta-analysis  
*Li YT, Xu H, Ye JZ, Wu WR, Shi D, Fang DQ, Liu Y, Li LJ*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Amedeo Lonardo, MD, Doctor, Senior Lecturer, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41126, Italy

**AIMS AND SCOPE**

*World Journal of Gastroenterology* (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. The *WJG* Editorial Board consists of 701 experts in gastroenterology and hepatology from 58 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, etc. The *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

**INDEXING/ABSTRACTING**

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2019 edition of Journal Citation Report® cites the 2018 impact factor for *WJG* as 3.411 (5-year impact factor: 3.579), ranking *WJG* as 35<sup>th</sup> among 84 journals in gastroenterology and hepatology (quartile in category Q2). CiteScore (2018): 3.43.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: *Yu-Jie Ma*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Subrata Ghosh, Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**

Ze-Mao Gong, Director

**PUBLICATION DATE**

September 7, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## *Helicobacter pylori* virulence genes

Anja Šterbenc, Erika Jarc, Mario Poljak, Matjaž Homan

**ORCID number:** Anja Šterbenc (0000-0001-8522-3753); Erika Jarc (0000-0001-8516-9179); Mario Poljak (0000-0002-3216-7564); Matjaž Homan (0000-0001-5764-5430).

**Author contributions:** All authors contributed equally to this paper, with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.

**Conflict-of-interest statement:** No potential conflicts of interest. No financial support.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Received:** May 18, 2019

**Peer-review started:** May 20, 2019

**First decision:** July 21, 2019

**Revised:** July 29, 2019

**Accepted:** August 7, 2019

**Article in press:** August 7, 2019

**Published online:** September 7, 2019

**P-Reviewer:** Amiri M, Chmiela M, Giordano A

**Anja Šterbenc, Erika Jarc, Mario Poljak,** Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana 1000, Slovenia

**Matjaž Homan,** Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana 1000, Slovenia

**Corresponding author:** Matjaž Homan, MD, PhD, Assistant Professor, Department of Gastroenterology, Hepatology and Nutrition, University Children's Hospital, Faculty of Medicine, University of Ljubljana, Bohoričeva 20, Ljubljana 1000, Slovenia.

[matjaz.homan@guest.arnes.si](mailto:matjaz.homan@guest.arnes.si)

**Telephone:** +386-1-5229276

**Fax:** +386-1-5229350

### Abstract

*Helicobacter pylori* (*H. pylori*) is one of the most important human pathogens, infecting approximately half of the global population. Despite its high prevalence, only a subset of *H. pylori* infected individuals develop serious gastroduodenal pathology. The pathogenesis of *H. pylori* infection and disease outcome is thus thought to be mediated by an intricate interplay between host, environmental and bacterial virulence factors. *H. pylori* has adapted to the harsh milieu of the human stomach through possession of various virulence genes that enable survival of the bacteria in the acidic environment, movement towards the gastric epithelium, and attachment to gastric epithelial cells. These virulence factors enable successful colonization of the gastric mucosa and sustain persistent *H. pylori* infection, causing chronic inflammation and tissue damage, which may eventually lead to the development of peptic ulcers and gastric cancer. Numerous studies have focused on the prevalence and role of putative *H. pylori* virulence genes in disease pathogenesis. While several virulence factors with various functions have been identified, disease associations appear to be less evident, especially among different study populations. This review presents key findings on the most important *H. pylori* virulence genes, including several bacterial adhesins and toxins, in children and adults, and focuses on their prevalence, clinical significance and potential relationships.

**Key words:** *Helicobacter pylori*; Virulence genes; Disease association; Children; Adults; Outer membrane proteins; Bacterial toxins

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The assessment of pathogenicity of a plethora of *Helicobacter pylori* (*H. pylori*) virulence genes appears to be relatively difficult. In specific, *H. pylori* isolates show a



S-Editor: Yan JP  
L-Editor: A  
E-Editor: Ma YJ



high degree of geographic variability, with certain *H. pylori* genotypes being associated with a more severe clinical outcome in some regions, while presenting as virtually harmless variants in other studied populations. To date, *cagA* and certain allelic variants of *vacA* have been most consistently associated with severe gastroduodenal disease in both children and adults, whereas the role of outer membrane proteins, such as *babA2*, *sabA*, *homB* and *oipA*, is somewhat more ambiguous.

**Citation:** Šterbenc A, Jarc E, Poljak M, Homan M. *Helicobacter pylori* virulence genes. *World J Gastroenterol* 2019; 25(33): 4870-4884

**URL:** <https://www.wjgnet.com/1007-9327/full/v25/i33/4870.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v25.i33.4870>

## INTRODUCTION

As one of the most common bacterial infections, *Helicobacter pylori* (*H. pylori*) infects approximately half of the world's population, although substantial regional variation exists<sup>[1]</sup>. The infection is usually acquired in childhood and persists lifelong in the absence of appropriate antibiotic treatment. In order to survive the harsh milieu of the human stomach, *H. pylori* had to adapt by possessing various virulence genes. However, the significance of these virulence genes extends beyond the pure survival needs of the bacteria, making *H. pylori* one of the most well-adapted human pathogens, capable of sustaining extremely efficient persistent infection. *H. pylori* has in fact developed mechanisms to withstand gastric acidity through the possession of urease and multiple sheathed flagella, which enable the bacteria to move toward gastric epithelial cells. *H. pylori* then needs to establish permanent colonization of the gastric mucosa, which is accomplished by the action of outer membrane proteins (OMPs) and adhesins, which enable adherence to the gastric epithelial cells. Finally, *H. pylori* possesses an arsenal of virulence genes that encode for effector proteins, which directly impair the gastric epithelium<sup>[2,3]</sup>. Although infection with *H. pylori* almost inevitably leads to chronic active gastritis, only approximately 10%-15% of infected individuals develop severe gastroduodenal diseases, such as peptic ulcer disease (PUD), gastric carcinoma (GC) and mucosa associated lymphoid tissue (MALT) lymphoma<sup>[4,5]</sup>. Nevertheless, the high global prevalence of *H. pylori* is considered an important public health issue, especially since *H. pylori* is classified as a class I carcinogen. More than one million (1033701) new cases of GC were estimated to occur worldwide in 2018, accounting for 6.1% of all new cancer cases, ranking GC as the fifth most common malignancy among males and females on a global scale<sup>[6]</sup>.

*H. pylori* infection in children and adults differs in several aspects. In children, it is thought that environmental factors, such as smoking, are implicated in disease development to a far lesser degree than in adults. Whereas several factors influence the prevalence rates of *H. pylori* infection in children (e.g., gender, age, low socioeconomic status and family education, poor hygiene, household crowding and certain geographical regions), it has been shown that the infection is acquired in early childhood in both industrialized and non-industrialized countries<sup>[7]</sup>. The most frequent form of gastritis in children is nodular gastritis, while atrophic gastritis and intestinal metaplasia, which occur more often in adults, are relatively rarely found in children<sup>[7]</sup>. Because the degree of *H. pylori* colonization and repertoire of virulence genes are comparable in both children and adults, it is thought that the lower levels of gastric inflammation and lower rates of severe clinical outcome in children indicate downregulation of immune responses<sup>[8]</sup>.

Over the past few decades, inclusion of proteomic and transcriptomic methods, as well as the availability of an increasing number of *H. pylori* partial and complete genomes, have significantly improved knowledge of the intricate gene regulatory networks of *H. pylori*. While the exact molecular mechanisms by which *H. pylori* infection induces a severe clinical outcome have not yet been clearly elucidated, they are thought to involve various elements, including host genetic and environmental factors, as well as certain bacterial virulence genes. In this review, we present the most important *H. pylori* virulence genes and discuss their prevalence and clinical significance in children and adults.

## GENES ENCODING OUTER MEMBRANE PROTEINS

OMPs are a large group of proteins that confer durable colonization of *H. pylori* through specific interactions with the host receptors. It has been estimated that approximately 4% of the *H. pylori* genome encodes OMPs, suggesting that these proteins are of vital importance to the bacterial lifecycle<sup>[3,9]</sup>. Several OMPs have been described in detail to date, with most studies focusing on *babA2*, *oipA*, *homB*, and *sabA* genes.

### *babA2*

To date, three allelic types of *bab* have been identified: *babA1*, *babA2* and *babB*. The *babA2* gene encodes a blood group antigen binding adhesin (BabA), a major adhesin on the outer bacterial membrane that enables binding of *H. pylori* to the mucosal Lewis<sup>b</sup> blood group antigens, thus facilitating colonization and determining bacterial density. Strains carrying the *babA2* gene can be classified based on protein production as BabA high producers (BabA-H), which possess Lewis<sup>b</sup> binding activity, and BabA low producers (BabA-L), which are not able to bind to Lewis<sup>b</sup> antigens, while strains carrying the *babA1* gene lack BabA. Unfortunately, PCR was used in most studies evaluating the prevalence and clinical significance of *babA2*, although it has been shown that this method does not accurately reflect the functional status of BabA as determined by Lewis<sup>b</sup> binding activity or immunoblotting<sup>[10,11]</sup>. Moreover, expression of BabA is generally regulated by phase variation and intragenomic recombination events between the *babA* gene and its highly homologous gene *babB*<sup>[11,12]</sup>.

**Adults:** The prevalence of the *babA2* gene varies significantly among different geographic regions, from moderate (44.0% and 44.6% in strains from Portugal and Germany, respectively) to high (70.4% and 79.7% in strains from Iran and United States, respectively) and even universal presence in strains from Japan, South Korea, Taiwan and Brazil<sup>[13]</sup>. *H. pylori* strains from East Asia uniformly express the BabA protein<sup>[10,14]</sup>, whereas only 9.8% of Western strains were shown to lack the BabA<sup>[10]</sup>.

A meta-analysis of 38 case-control studies evaluating the relationship between the presence of the *babA2* and clinical outcome showed that detection of the *babA2* gene significantly increases the risk of PUD [odds ratio (OR) = 2.069, 95% confidence interval (CI): 1.532-2.794], especially in the duodenal ulcer subgroup (OR = 1.588, 95% CI: 1.141-2.209), with significant associations being more apparent in studies on Western isolates. Namely, the presence of the *babA2* gene substantially increased PUD risk in Western populations (OR = 2.739, 95% CI: 1.860-4.032), whereas the association with PUD was only marginal in Asian populations (OR = 1.370, 95% CI: 0.941-1.994), due to the very high overall prevalence of the *babA2* gene. Conversely, no significant risk correlation was observed for GC among Western (OR = 1.303, 95% CI: 0.881-1.927) or Asian populations (OR = 1.132, 95% CI: 0.763-1.680)<sup>[13]</sup>. The lack of association found in this meta-analysis could be due to significant heterogeneity among the performed studies, contradicting several reports that suggest *babA2* is indeed an important virulence factor in GC development, especially when co-expressed with other virulence factors. For example, it has been shown that the “triple-positive” genotype, simultaneously containing *babA2*, *vacA* s1 and *cagA*, serves as a better discriminative factor for PUD and GC than the *vacA* s1 and *cagA* only genotype<sup>[15]</sup>. Moreover, a study focusing on expression of the BabA protein has shown that patients from Western countries with BabA-H and BabA-L had a 18.2- (95% CI: 1.7-198) and 33.9-fold (95% CI: 2.8-411) increased risk of GC compared to those who were *babA2* negative<sup>[10]</sup>. Interestingly, a recent genome-wide association study on 173 European *H. pylori* isolates showed that, compared to strains obtained from gastritis patients, the GC phenotype was associated with certain single nucleotide polymorphisms and a specific array of genes, including the *babA2* gene<sup>[16]</sup>. Although the majority of studies on isolates from East Asia have failed to find an association between the *babA2* gene and disease status, a study from Taiwan highlighted the importance of the recombinant *babA/B* genotype, which was found to be associated with both precancerous lesions and GC<sup>[12]</sup>.

**Children:** Data on the significance of the *babA2* gene in children is less abundant. To date, nine studies have evaluated the prevalence and clinical relevance of the *babA2* gene in children<sup>[17-20]</sup>. The prevalence ranged from 17.2% in Portuguese<sup>[21,22]</sup> to 84.4% in Brazilian strains<sup>[23]</sup>. Moreover, associations between the *babA2* gene and clinical outcome are inconsistent<sup>[17,24,25]</sup>, with only two studies<sup>[17,22]</sup> correlating the presence of the *babA2* gene with a higher degree of gastric mucosal damage.

**Associations with other virulence genes:** The influence of the *babA2* gene on clinical outcome is generally associated with *cagA*, *vacA* s1, *vacA* m1<sup>[17]</sup> and *oipA* “on” status<sup>[26,27]</sup>.

**Comment:** Unfortunately, despite a multitude of clinical and epidemiological studies that have attempted to identify possible links between the presence of the *babA2* gene and disease outcome, definite conclusions are difficult to reach, due to several factors that influence interpretation of the results. In addition to the distinct genotypic profile of Western and Asian isolates, considerable performance differences in *babA2* gene detection methods<sup>[17]</sup>, as well as poor correlation between the presence of the *babA2* gene and actual expression and activity of the BabA2 protein<sup>[10]</sup>, thus prevent simple comparisons between studies.

### Outer inflammatory protein A

Outer inflammatory protein A (OipA) is encoded by the *oipA* gene and its expression is thought to be dependent on a slipped strand mispairing system. The proposed mechanisms by which a functional OipA (e.g., *oipA* “on” status) promotes severe gastric pathology include the capacity of the bacteria to attach to the gastric epithelium, followed by subsequent apoptosis of host cells, toxicity and the induction of inflammation through increased interleukin-8 (IL-8) production<sup>[28-35]</sup>.

**Adults:** The overall prevalence of *oipA* “on” status in adult patients was shown to be remarkably consistent among certain geographical regions: Approximately 100%, 80% and 60% of East Asian, Latin American and Western strains, respectively, contained *oipA* “on” (Table 1). Unfortunately, the clinical significance of the *oipA* status remains controversial, although numerous studies have investigated its relevance. It has been proposed by some authors that OipA increases the risk for PUD and GC development by disrupting the balance between apoptosis and cell proliferation during *H. pylori* infection, causing PUD when apoptosis is promoted and metaplasia and GC when gastric cell proliferation is increased<sup>[36-39]</sup>. A meta-analysis of PUD and GC risk, based on *oipA* “on/off” status, showed increased overall risk of PUD (OR = 3.97, 95%CI: 2.89-5.45) and GC (OR = 2.43, 95%CI: 1.45-4.07) in individuals with *oipA* “on” status, while the presence of the *oipA* gene alone did not reflect its specific functional status, since it was not found to be associated with PUD or GC<sup>[40]</sup>. However, results from some studies contradict the findings from this meta-analysis, since no correlation between *oipA* and disease status or increased gastroduodenal damage was identified<sup>[27,31,32,35]</sup>. Moreover, it seems that *oipA* status by itself is not a useful marker for predicting the clinical outcome of *H. pylori* infection, especially in populations with a high prevalence of infection with virulent strains<sup>[32]</sup>.

**Children:** In children, the frequency of the *oipA* “on” status tends to be somewhat lower than in adults (49.6%, 67.6% and 68.8% in children from Portugal, United States and Brazil, respectively)<sup>[22,30,41]</sup>, with higher frequencies among pediatric strains from high risk populations in which the incidence of *H. pylori* infection and related disease is significant. Moreover, the OR for PUD risk was shown to be higher in children (OR= 7.03, 95%CI: 3.71-13.34) compared to that in adults, suggesting increased risk for PUD in children with *oipA* “on” status<sup>[40,42]</sup>. However, the observed differences between children and adults regarding the significance of *oipA* status were based on a relatively small number of strains tested and thus need to be confirmed in future studies.

**Associations with other virulence genes:** The *oipA* “on” status was found to be closely associated with *cagA* positivity<sup>[26,27,33,38]</sup>, although it has also been linked to the presence of other *H. pylori* virulence genes, such as *vacA* s1<sup>[27,33,38]</sup>, *vacA* m1<sup>[26,27,33]</sup>, *vacA* m2<sup>[33]</sup> and *babA2*<sup>[26,27]</sup>.

### homB

The *hom* family contains four OMPs, of which *homA* and *homB* are the most studied. Strains can carry a single *homA* or *homB* gene, with one locus remaining empty, two copies of each gene (*homA/homA* or *homB/homB*), a single copy of each gene (*homA/homB*), or they can lack *homA* and *homB* genes, leaving both loci empty. HomB enables adherence to host gastric epithelial cells and has been shown to increase cellular IL-8 production *in vitro*<sup>[42]</sup>. The level of adherence and IL-8 secretion is proportional to the number of *homB* copies with strains that carry two copies of the *homB* gene, inducing more pronounced actions, leading to a higher degree of gastric mucosal damage<sup>[42]</sup>.

**Adults:** Studies have found a relatively comparable prevalence of the *homB* gene in Western countries, with slightly more than half of the evaluated strains being *homB* positive (Table 2). However, it seems that the *homB* gene is more common in East Asia and West Africa than in the Middle East, where only approximately one third of strains contain *homB* (Table 2). In addition, the distribution, location and copy number of the *homB* gene seem to be dependent on geographical region, influencing potential



**Table 1** Prevalence of *oipA* “on” status among isolates from various geographical regions

Country	Number of patients	Study population	<i>oipA</i> “on” prevalence	Association with other virulence genes
North-Eastern Brazil <sup>[30]</sup>	95	Adults with gastritis, GC and their first degree relatives, asymptomatic children	81.1%	<i>cagA</i> , <i>vacA</i> s1 m1
Iran <sup>[31]</sup>	53	Adults and children with chronic gastritis, PUD, intestinal metaplasia and GC	79.0%	<i>cagA</i> , <i>vacA</i> s1 m1
Venezuela <sup>[32]</sup>	113	Adults with chronic gastritis	83.0%	NA
Bulgaria <sup>[33]</sup>	70	Symptomatic adults	81.0%	<i>cagA</i> , <i>vacA</i> s1, m1 and m2
Malaysia and Singapore <sup>[34]</sup>	159	Adults with functional dyspepsia, GC and PUD	89.4%	<i>vacA</i> m1/m2
Italy <sup>[35]</sup>	90	Adults with chronic gastritis and PUD	77.4%	<i>babA2</i> , <i>hopQ</i>
Colombia and United States <sup>[36]</sup>	200	Patients with gastritis, PUD and GC	79.3%	<i>cagA</i> , <i>babA</i>
Germany <sup>[26]</sup>	58	Patients with chronic gastritis	59.0%	<i>cagA</i> , <i>vacA</i> s1, <i>babA</i>
Netherlands <sup>[37]</sup>	96	Adults with chronic gastritis, PUD, GC and lymphoma	72.0%	<i>cag</i> PAI+
Italy <sup>[27]</sup>	60	Adults with chronic gastritis, PUD and duodenitis	60.0%	<i>cagA</i> , <i>vacA</i> s1 and m1, <i>babA</i>
East Asia and India <sup>[38]</sup>	54	Adults with gastritis and PUD	100.0%	<i>cagA</i> , <i>vacA</i> s1
Western countries <sup>[38]</sup>	55	Adults with gastritis and PUD	63.6%	<i>cagA</i> , <i>vacA</i> s1

NA: Not available; PUD: Peptic ulcer disease; GC: Gastric cancer.

differences in disease outcome<sup>[42,43]</sup>. Whereas Western strains carry a single *hom* gene at locus A, East Asian strains only carry a single *hom* gene at locus B<sup>[42,44]</sup>. Interestingly, strains from Iran were shown to carry only one of the *hom* genes, *homA* and *homB* were not detected simultaneously in any of the 138 evaluated strains<sup>[45]</sup>.

Whereas the two genes exhibit 90% sequence identity, they are correlated with different spectra of the disease<sup>[46-51]</sup>; *homA* has been associated with non-ulcer dyspepsia (NUD), whereas *homB* is presumed to be implicated in the development of PUD and GC, although this association is geographically dependent (Table 2). Moreover, strains carrying two copies of the *homB* gene were found to be most strongly correlated with PUD (OR = 4.91, 95%CI: 1.77-14.02)<sup>[42]</sup>.

**Children:** Only three studies<sup>[22,42,50]</sup> have specifically focused on the prevalence and clinical significance of the *homB* gene in children. Whereas two studies from Portugal found a strong association between *homB* and PUD<sup>[22,42]</sup>, *homB* was not considered to be an important individual virulence factor in Slovenian children and was only associated with a higher degree of mucosal damage when co-present with other virulence genes (i.e., *cagA*, *vacA* and *babA2*)<sup>[50]</sup>.

### **sabA**

In addition to Lewis<sup>b</sup> blood group antigens, sialyl-Lewis<sup>x</sup> and sialyl-Lewis<sup>a</sup> antigens are considered to be functional receptors, enabling *H. pylori* adherence. They are recognized by the corresponding sialic acid binding adhesin SabA, encoded by the *sabA* gene. In contrast to SabA, its homologue SabB does not seem to be able to bind to sialyl-Lewis<sup>x</sup> and sialyl-Lewis<sup>a</sup> receptors. Similar to *oipA*, the expression of SabA is regulated by phase variation, meaning only certain strains are capable of producing functional proteins<sup>[52,53]</sup>. The level of expression of SabA can rapidly adjust to the changing environment of the human stomach by switching “on” or “off”. The sialyl-Lewis<sup>x</sup> and sialyl-Lewis<sup>a</sup> antigens are otherwise rarely present in normal gastric mucosa, and only after persistent *H. pylori* infection induces chronic inflammation of the gastric mucosa does replacement of naturally produced Lewis antigens occur<sup>[53]</sup>. Moreover, the *sabA* “on” status inversely correlates with the degree of gastric acid secretion, suggesting that differences in pH and/or antigen expression on atrophic mucosa can influence SabA expression<sup>[53]</sup>.

**Adults:** In adults, *sabA* “on” was found in 63.2%, 49.0% and 35.5% of strains from

**Table 2 Overview of studies on *homb* prevalence and clinical significance in adults and children**

Country	Study population	Number of patients	<i>homb</i> prevalence	Clinical relevance of <i>homb</i>	Association with other virulence genes
Western countries <sup>[43]</sup>	Adults	234	53.8	Significant, PUD	<i>vacA</i> s1, <i>cagA</i> +
East Asian countries <sup>[43]</sup>	Adults	138	86.8	NS	NS
Western countries <sup>[46]</sup>	Adults	300	56.0	NA	NA
East Asian countries <sup>[46]</sup>	Adults	138	86.6	NA	NA
Burkina Faso <sup>[46]</sup>	Adults	11	90.9	NA	NA
Colombia, United States <sup>[47]</sup>	Adults	286	61.2	Significant, GC	<i>cagA</i> +
Iran <sup>[45]</sup>	Adults	138	43.5	Significant, GC	<i>cagA</i> +
Iraq <sup>[48]</sup>	NA	70	29.9	NS	NS
Turkey <sup>[48]</sup>	NA	64	33.9	NS	NS
South Korea <sup>[44]</sup>	Children and adults	260	69.2	NS	<i>vacA</i>
Portugal <sup>[49]</sup>	Children	45	58.4	Significant, PUD	NA
	Adults	90	57.7	NS	NA
Portugal <sup>[42]</sup>	Children	84	57.3	Significant, PUD	<i>cagA</i> +, <i>vacA</i> s1, <i>babA2</i> +, <i>hopQI</i> , <i>oipA</i> "on"
	Adults	106	56.8	Significant only in ≤ 40 yr of age, PUD	
Portugal <sup>[22]</sup>	Children	117	53.5	Significant, PUD	<i>jhp0562</i>
Slovenia <sup>[50]</sup>	Children	285	40.7	NS	NS

NS: Non-significant; NA: Not available; PUD: Peptic ulcer disease; NUD: Non-ulcer dyspepsia; GC: Gastric cancer.

Portugal<sup>[42]</sup>, the Netherlands<sup>[37]</sup> and Italy<sup>[35]</sup>, respectively. The rates are higher in Iran, with *sabA* "on" being detected in 85.3% of strains<sup>[31]</sup>. Similarly, functional *sabA* was found to be highly prevalent in Japan, it was present in 81.5% of patients with chronic gastritis, PUD and GC<sup>[54]</sup>. Interestingly, an analysis of strains from Taiwan showed that the *sabA* gene was present in 80.0% (116/145) of strains, whereas only 31.0% (45/145) actually expressed SabA<sup>[14]</sup>.

In a study on 200 patients from Colombia and the United States, *sabA* "on" status was shown to be associated with the presence of pre-neoplastic lesions (e.g., gastric atrophy and severe intestinal metaplasia) and GC. Moreover, *sabA* "on" was the only predictor of GC versus duodenal ulcer (OR = 2.8, 95%CI: 1.2-6.7) among several investigated OMPs in this study<sup>[36]</sup>. However, there were no statistically significant differences among Taiwanese patients with *sabA* "on" and *sabA* "off" in terms of the prevalence of gastric atrophy or intestinal metaplasia<sup>[14]</sup>. Although all *H. pylori* isolates from Iranian patients with GC were found to be *sabA* "on" (5/5, 100%), the link did not appear to be statistically significant<sup>[31]</sup>. Similarly, there was no correlation between *sabA* "on" and clinical outcome among Italian and Japanese patients<sup>[35,54]</sup>, although *sabA* "on" was associated with atrophy and severe neutrophil infiltration in patients from Japan<sup>[54]</sup>.

**Children:** In children, the prevalence of the *sabA* "on" genotype was found to be 44.0% among strains from Portugal and the *sabA* "on" status significantly correlated with NUD ( $P = 0.028$ , OR = 0.298)<sup>[42]</sup>. Similarly, a low rate of SabA producing strains (38.0%) was detected in a collection of gastric biopsies from children and young adults<sup>[55]</sup>. Interestingly, it has recently been proposed that high expression of *sabA* may be responsible for iron deficiency anemia in children and young adults<sup>[56]</sup>.

**Associations with other virulence genes:** Studies evaluating associations between *sabA* and other virulence genes are somewhat contradictory. Whereas *sabA* was closely related to *cagA* and *babA2* positivity in European strains<sup>[52]</sup>, subsequent studies could not confirm these findings<sup>[36,37]</sup>.

**Comment:** Again, identification of the *sabA* "on" status by using PCR and sequencing may not reliably reflect the actual production of SabA, thus affecting the result interpretation of studies on *sabA* clinical relevance, which have primarily used sequencing-based methods<sup>[3,14]</sup>.

## VIRULENCE GENES THAT PRODUCE TOXINS AND CAUSE HOST TISSUE DAMAGE

### *cagA*, *cagPAI* and *EPIYA* motifs

It has been previously shown that highly virulent *H. pylori* strains harbor the cytotoxin-associated genes pathogenicity island (*cagPAI*), which is a 40 kb region containing 31 genes that encode for components of a type IV secretion system, involved in CagA translocation and the host's inflammatory response<sup>[4]</sup>. *cagA* is arguably the most extensively studied *H. pylori* virulence gene to date. It is located at the end of the *cagPAI* and encodes a 120-145 kDa immunodominant protein, CagA<sup>[57]</sup>. Based on CagA production, *H. pylori* isolates can be divided into two groups: *cagA* negative and *cagA* positive. During infection, CagA is localized on the plasma membrane, where it is phosphorylated at specific Glu-Pro-Ile-Tyr-Ala (EPIYA)-motifs by host Src and Abl kinases. Four distinct segments harboring EPIYA-motifs have been described so far, designated as segments A, B, C, and D<sup>[11,57,58]</sup>. The biological activity of CagA depends on the number and types of the EPIYA-motifs at the C-terminal region. Following translocation, CagA interacts with multiple host cell molecules and is responsible for dysregulation of homeostatic signal transduction of gastric epithelial cells, induction of pro-inflammatory responses that lead to chronic inflammation of gastric mucosa, and induction of carcinogenesis through the modulation of apoptosis, disruption of cell polarity and promotion of genetic instability. Hence, due to its cancer-inducing traits, CagA was designated as the first bacterial oncoprotein<sup>[57,59]</sup>.

**Adults:** An analysis of a global collection of *H. pylori* strains from 53 different geographical/ethnic sources showed the presence of *cagPAI* in more than 95% of strains from Western and South Africa and East and Central Asia, whereas the presence of *cagPAI* in other regions ranged from 81% (Northeastern Africa) to only 28% (Latin America). The prevalence of *cagPAI* in Europe was shown to be intermediate, with approximately 58% of strains harboring *cagPAI*<sup>[60]</sup>. The prevalence of *cagA* positive strains is approximately 60% and > 90% in Western and Asian countries, respectively<sup>[2]</sup>. In the Middle East, *cagA* is detected in nearly half of the strains<sup>[61]</sup>.

Since the majority of East Asian strains harbor *cagA* irrespective of the disease status, it cannot be considered a useful marker of the disease. Nevertheless, based on mosaicism within the EPIYA-motifs, *cagA* positive strains can be further divided into Western (EPIYA-ABC, EPIYA-ABCC and EPIYA-ABCCC) and East Asian strains (EPIYA-ABD)<sup>[5,62]</sup>. Although very rarely, a subset of East Asian strains can possess a Western type EPIYA motif, whereas the reverse is not true for Western strains<sup>[32,58]</sup>. In Latin America, EPIYA-ABC is the most common motif, detected in approximately 51.6%-73.6% of strains, although strains with multiple EPIYA-C segments were found to be rare (2.7%) in a Venezuelan population<sup>[32]</sup>.

When assessing the risk of infection with *cagA* positive strains for the development of GC, one must be aware of the considerable global variation, not only in the prevalence of *cagA* positive strains but also in the incidence of GC<sup>[60,63]</sup>. In Western countries, the presence of *cagA* is associated with a higher risk of GC and PUD development, whereas in East Asia, where almost all *H. pylori* strains contain *cagA*, this association is evident but less prominent<sup>[5]</sup>. Specifically, patients infected with *H. pylori* who had CagA antibodies were shown to have a 5.8-fold (95%CI: 2.6-13.0) increase in the likelihood of developing GC compared to uninfected individuals, whereas those who were CagA seronegative only had a slightly but not statistically significantly (OR 2.2, 95%CI: 0.9-5.4) increased risk of GC<sup>[64]</sup>. Moreover, a meta-analysis of CagA serostatus performed on 10 non-cardia gastric cancer case-control studies from Western populations showed marked differences in CagA seropositivity in *H. pylori* infected cases (62.8%, *n* = 1707) and controls (37.5%, *n* = 2124), with CagA seropositive status associated with a higher risk of GC development (OR = 2.87, 95%CI: 1.95-4.22) compared to the risk of being infected with *H. pylori* only (OR = 2.31, 95%CI: 1.58-3.39)<sup>[65]</sup>. Similarly, a meta-analysis of 10 gastric cancer case-control studies from East Asia also identified an association between CagA seropositivity and increased risk of GC<sup>[66]</sup>, although OR (OR = 1.81, 95%CI: 1.30-2.11) was lower compared to that of Western populations<sup>[65,66]</sup>. In addition, a large meta-analysis on more than 17000 individuals identified a 1.69-fold risk (95%CI: 1.12-2.55) of PUD among *cagA* positive Western and Asian populations, with an even higher risk of GC (OR = 2.09, 95%CI: 1.48-2.94)<sup>[67]</sup>. CagA is also one of the few virulence factors associated with the development of gastric high-grade B cell lymphoma<sup>[11]</sup>.

Different diagnostic approaches should be applied in different geographical regions—due to the almost universal presence of the *cagA* gene in East Asian strains,

the sensitivity of *cagA* gene detection is suboptimal, rendering *cagA* subtyping in order to identify those with high risk infections<sup>[11]</sup>. The number of EPIYA segments in the second repeat region is thought to be associated with GC. Namely, initial trials showed that the incidence of GC was considerably higher if patients were infected with strains harboring multiple EPIYA-C segments (EPIYA-ABCCC) than if patients were infected with strains harboring only one EPIYA-C segment (EPIYA-C). Unfortunately, because East Asian strains only harbor a single EPIYA-D segment, differentiation between chronic gastritis and GC using only the number of repeat regions has proved to be somewhat problematic<sup>[5,62]</sup>. To clarify this issue, a recent meta-analysis evaluated the differences in PUD and GC risk among strains carrying one EPIYA-D motif or multiple EPIYA-C motifs. In Asian strains, the presence of one EPIYA-D motif was significantly associated with increased GC risk (OR = 1.91, 95%CI: 1.19-3.07) compared with the presence of one EPIYA-C motif, whereas it was not significantly associated with PUD (OR = 0.90, 95%CI: 0.46-1.76). Moreover, multiple EPIYA-C motifs were associated with increased PUD risk (OR = 2.33, 95%CI: 1.29-4.20) in Asian countries and with increased GC risk (OR = 3.28, 95%CI: 2.32-4.64) in Western countries<sup>[68]</sup>.

**Children:** In children, *cagA* is the best characterized among all virulence genes. Similar to adults, the prevalence of *cagA* in children varies among different countries/regions. The *cagA* gene can be found in more than half of *H. pylori* isolates obtained from symptomatic children from Western countries, namely 60.8% in Poland<sup>[18]</sup>, 59.6% in Slovenia<sup>[69]</sup> and 70.0% in United States<sup>[41]</sup>. A surprisingly low prevalence of *cagA* was found in Portuguese children (22.4%)<sup>[21]</sup>. In Iran, the reported prevalence of *cagA* in symptomatic children ranges between 60.0 and 72.7%<sup>[70,71]</sup> and is similar to that in Turkish children (55.6%-61.0%)<sup>[25,72]</sup>. A high prevalence of *cagA* (73.0%) was also observed in symptomatic Venezuelan children with recurrent abdominal pain<sup>[73]</sup>. In Mexican children, *cagA* and *cagPAI* were detected in 63.3% and 71.4% of strains, respectively<sup>[74]</sup>. Similar to adults, strains from Korean and Japanese children almost exclusively carry the *cagA* gene (94.0% and 100%, respectively)<sup>[75,76]</sup>. Interestingly, it has previously been shown that the prevalence of *cagA* can be surprisingly high (66.1% and 75.0% in Colombia and Brazil, respectively) in asymptomatic children from high-risk populations, with rates that are comparable or even higher than those in symptomatic children from other regions<sup>[30,77]</sup>. It is thus possible that the high prevalence of virulent *H. pylori* variants in Colombian and Brazilian children contributes to the increased GC incidence in adults from the same region<sup>[77]</sup>. The high proportion (40.0%) of strains with multiple EPIYA-C motifs further confirms previous observations that this population may already be exposed to the most virulent variants of *H. pylori* at a young age<sup>[30]</sup>. The fact that infection with *H. pylori* is a risk factor for GC highlights the importance of early detection of *H. pylori* virulence factors in children, especially those residing in areas with a high prevalence of GC<sup>[77]</sup>.

In China, the rates of *cagA* positivity in the pediatric population closely resemble those in adults, with the prevalence of *cagA* among children with symptomatic gastroduodenal disease being 94.4%, with no clinical relevance<sup>[78]</sup>. Similarly, because the *cagA* positive genotype is present in virtually all Korean and Japanese pediatric strains, no associations with severity of gastritis or PUD were found<sup>[75,76]</sup>. In contrast, *cagA* was significantly associated with PUD (OR = 14.06, 95%CI: 4.78-41.29)<sup>[42]</sup>, higher *H. pylori* density score, and the degree of chronic and acute inflammation<sup>[69]</sup> in European children.

**Associations with other virulence genes:** Interestingly, almost all *vacA* s1 strains also carry *cagA*, whereas almost all *cagA* negative strains harbor the less virulent genotype *vacA* s2/m2<sup>[69,79]</sup>. In addition, *cagA* is also more commonly detected in *babA2* positive strains<sup>[77]</sup>.

### Vacuolating cytotoxin A

The vacuolating cytotoxin A (VacA) derives its name from its capacity to induce the formation of vacuoles in eukaryotic cells. Several other cellular functions of VacA with a potential influence on host cell death have been described thus far, including disruption of endocytic trafficking, release of organic anions and HCO<sub>3</sub><sup>-</sup>, promotion of immune tolerance and chronic infection through inhibition of various immune cells, activation of mitogen-activated protein kinases, and modulation of autophagy<sup>[80,81]</sup>. All *H. pylori* strains carry the *vacA* gene, although with different vacuolating ability, which is conferred by variations in five *vacA* regions: s-region (s1 and s2), i-region (i1, i2, i3), m-region (m1 and m2), d-region (d1 and d2), and the recently identified c-region (c1 and c2). The *vacA* s2 variant is considered less pathogenic than the s1, since VacA s2 toxins are produced and secreted at lower rates and are also unable to form



membrane channels through which VacA s1 induces vacuolation of cells<sup>[3,79,81]</sup>. VacA i1 is also associated with increased activity compared to VacA i2. Unlike VacA m2, VacA m1 induces a decrease in intracellular levels of glutathione and an increase in oxidative stress, leading to autophagy and apoptosis of host cells<sup>[81,82]</sup>.

**Adults:** The distribution of *vacA* alleles is geographically dependent, with s1c being the most prevalent allele in East Asia, while the *vacA* s1a allele is detected more often in Northern Europe and *vacA* s1b in Portugal and Spain. In Northern America, *vacA* s1a and *vacA* s1b are relatively evenly distributed, whereas virtually all strains from Latin America carry *vacA* s1b. The *vacA* s1 allele prevalence ranges from 36.0% in North Africa to 95.0% in East Asia. *vacA* m1 and m2 are equally distributed, except in Portugal, Spain and Latin America, where *vacA* m1 is more prevalent (86.2%). The *vacA* m2b allele is found solely in East Asian strains carrying *vacA* s1c<sup>[83]</sup>. Interestingly, mixed *vacA* s1a/s1b/m2 was found to be the most common genotype in Saudi Arabia<sup>[61]</sup>.

Several studies have intensely focused on potential associations between *vacA* alleles and risk of PUD and GC. Results were relatively consistent, since most studies identified *vacA* s1, *vacA* i1 and *vacA* m1 alleles as being associated with a higher risk of precancerous lesions and GC<sup>[67,84]</sup>. Interestingly, *vacA* i1 and d1 were shown to be significantly associated with non-cardia GC (OR = 37.52, 95%CI: 3.04-462.17 and OR = 7.17, 95%CI: 1.43-35.94, respectively), but not with cardia GC. The presence of these alleles may also predict the risk according to the GC type, as *vacA* i1 was linked to intestinal-type adenocarcinoma (OR = 14.04, 95%CI: 2.15-91.77) and *vacA* d1 to diffuse-type adenocarcinoma (OR = 7.71, 95%CI: 1.13-52.28)<sup>[85]</sup>. Furthermore, strains harboring *vacA* s1 and *vacA* m1 genotypes were also more commonly detected in patients with severe inflammation and gastric epithelial damage and PUD than in those who were *vacA* s2/m2 positive. In Western countries and the Middle East, the presence of *vacA* s1/m1 is associated with an increased risk of PUD, whereas in East Asia, the *vacA* s1/i1/m1 genotype is not a useful differentiating factor since most strains harbor this genotype<sup>[11,34,61]</sup>. Moreover, a meta-analysis showed that *vacA* i1 confers higher risk of GC (OR = 5.12, 95%CI: 2.66-9.85), especially among the Central Asian population (OR = 10.89, 95%CI: 4.11-20.88). Conversely, *vacA* i1 was not associated with increased risk of PUD (OR = 1.38, 95%CI: 0.87-2.17)<sup>[86]</sup>. As shown by Van Doorn et al<sup>[83]</sup>, the *vacA* s1/*cagA*+ genotype is associated with PUD in all regions of the world.

**Children:** Genotype *vacA* s1/m2 is the most common genotype in children from Iran (45.5%) and Turkey (57.1%)<sup>[25,70]</sup>. In Venezuela, 85.0% of strains obtained from symptomatic children harbored *vacA* s1/m1<sup>[73]</sup>. In Slovenia, pediatric *H. pylori* strains more commonly contain *vacA* s1 and m2 than *vacA* s2 and m1, with most strains harboring the *vacA* s1/m1 genotype<sup>[17,50,69]</sup>. In asymptomatic Brazilian children, *vacA* s1 (82.5%) and *vacA* i1 (75.0%) were the most common alleles, whereas m1 and m2 were found to be equally distributed (48.2% each)<sup>[30]</sup>. Using stool samples, the prevalence of the *vacA* s1 gene in asymptomatic Colombian children was shown to be very high (91.7%) and similar to that in the adult population (93.2%)<sup>[77]</sup>. Results from Brazil, a high-risk region for GC, also suggest that asymptomatic children from this area are more often colonized with strains harboring the toxigenic *vacA* s1 allele<sup>[87]</sup>.

In Iranian children, nodular gastritis was commonly found and was significantly associated with the presence of *vacA* m1<sup>[70]</sup>. Similar to *cagA*, *vacA* s1 has been strongly associated with PUD risk (OR = 14.13, 95%CI: 4.75-42.04) among Portuguese children<sup>[42]</sup>, whereas there were no significant correlations between *vacA* status and PUD in Iranian children<sup>[71]</sup>. Moreover, studies on Korean, Japanese and North American children found no associations between the *vacA* genotype and clinical outcome or severity of inflammation<sup>[75,76,88,89]</sup>.

**Associations with other virulence genes:** Compared to *vacA* s2, strains that harbor *vacA* s1 more commonly contain *cagPAI*, *babA2*, *homB* and *oipA* "on"<sup>[81]</sup>. *vacA* i1 is strongly associated with *vacA* s1 and *vacA* m1 and *cagA*<sup>[30,84]</sup>.

## VIRULENCE GENES WITH OTHER FUNCTIONS

### Duodenal ulcer promoting gene

The duodenal ulcer promoting (*dupA*) gene encompasses *jhp0917* and *jhp0918*, located in the plasticity region of the *H. pylori* genome. Due to its high homology with the *virB4* factor, *dupA* presumably forms a type IV secretion system together with *vir* genes, although its exact functions are not yet fully understood. The detection of the *dupA* gene correlates with increased IL-8 production from gastric epithelial cells, both



*in vivo* and *in vitro*. Increased IL-8 secretion from the gastric antrum thus leads to the development of predominantly antral gastritis, a well-known characteristic of duodenal ulcer disease<sup>[90]</sup>.

**Adults:** Worldwide, approximately 48.0% of strains carry *dupA*<sup>[91]</sup>, with the highest rates in Brazil (89.5%) and South Africa (84.8%)<sup>[92,93]</sup> and lowest in East Asian countries<sup>[91]</sup>. A study on 500 isolates from patients with gastritis, PUD and GC originating in Japan, Korea and Colombia showed an overall prevalence of *dupA* of 26.3%<sup>[94]</sup>. Surprisingly, the prevalence of the *dupA* gene was higher in Colombia (36.5%) than in Korea (16.8%), regardless of the clinical outcome<sup>[94]</sup>. In relation to the prevalence in strains from patients with functional dyspepsia, *dupA* was detected in 65.0%, 37.8%, 35.7%, 28.9% and 7.1% of strains from Swedish, Australian, Malay, Chinese and Indian patients, respectively<sup>[95]</sup>.

Interestingly, in contrast to other virulence factors, such as *cagPAI*, *vacA*, *oipA* and *babA2*, which are reportedly associated with an increased risk of both PUD and GC, *dupA* was the first *H. pylori* virulence factor to be correlated with a differential susceptibility to PUD and GC, with protection against pre-neoplastic lesions and GC (OR for GC = 0.42, 95%CI: 0.2-0.9, compared with gastritis)<sup>[94]</sup>. However, some subsequent studies failed to reproduce these results. A meta-analysis on the relationship between the *dupA* gene and clinical outcomes was therefore performed and it showed that infection with *H. pylori* strains carrying *dupA* had a 1.41-fold (95%CI: 1.12-1.76) increased overall risk of duodenal ulcer. A subgroup analysis identified higher ORs in Asian countries (OR 1.57, 95%CI: 1.19-2.06) than in Western countries (OR 1.09, 95%CI: 0.73-1.62), suggesting that *dupA* can be considered a disease-specific virulence factor, especially in Asian countries. No associations between the presence of *dupA* and GC or gastric ulcer were found<sup>[66]</sup>. In addition, the same authors reported that the presence of *dupA* may also be an independent risk factor (OR = 3.71, 95%CI: 1.07-12.38) for *H. pylori* eradication failure<sup>[90]</sup>. Interestingly, a recent study showed protective effects of the *dupA* gene against severe outcome in infected females (OR = 0.05, 95%CI: 0.01-0.42). Moreover, whereas the sole presence of *vacA* i1 carried the highest risk for a severe clinical outcome, the simultaneous presence of the *dupA* gene resulted in a delay of severe disease outcome by almost 20 years<sup>[96]</sup>.

**Children:** The prevalence of *dupA* was found to be 37.5% in Mexican children with recurrent abdominal pain<sup>[74]</sup>. In contrast, all *H. pylori* strains from Brazilian children were found to be *dupA* positive, with a significantly higher prevalence than in adults from the same region<sup>[92]</sup>. However, despite using the same primers for detecting the *dupA* gene as Gomes *et al*<sup>[92]</sup>, another study analyzing Brazilian children showed a much lower (37.0%) prevalence of this gene<sup>[97]</sup>. These discrepancies may be due to the presence of significant geographic differences even within the same country/region, variations in studied populations or rearrangements within the plasticity zone, which is prone to frequent change<sup>[92,97]</sup>.

**Associations with other virulence genes:** The *dupA* gene has previously been associated with *cagA*<sup>[74,92,97]</sup> and *cagPAI*<sup>[74]</sup>.

## COMBINATIONS OF VIRULENCE GENES

Since some genes are almost exclusively associated with one another (e.g., *vacA* s1/i1/m1 and *cagA*), it is impossible to consider each of these virulence genes separately as independent markers for disease outcome. For example, the presence of *oipA* “on” is tightly linked to the presence of *cagPAI* and some studies even suggest that *cagPAI* and *OipA* act synergistically by regulating the signaling pathways that induce inflammation and actin dynamics<sup>[29]</sup>. Here, we briefly summarize some of the most intriguing combinations of *H. pylori* virulence genes.

As expected, the risk of a severe clinical outcome increases if multiple virulence genes are simultaneously detected. It has been shown that strains harboring the *vacA* s1/m1/*cagA* genotype carry a 4.8-fold (95%CI: 1.71-13.5) increased risk of progression of pre-cancerous lesions in comparison to the strains carrying *vacA* s2/m2/*cagA*-, with higher ORs than if each of these virulence genes was evaluated individually<sup>[98]</sup>. In addition, strains carrying *cagA*, *vacA* s1 and *babA2* were associated with duodenal ulcer and adenocarcinoma<sup>[15]</sup>, whereas *cagA*, *vacA* s1/m1 and *babA2* were found to work synergistically in causing intestinal metaplasia<sup>[27]</sup>. Furthermore, a study from Portugal identified an increased risk of PUD in strains that simultaneously harbored *homB*, *cagA* and *vacA*<sup>[43]</sup>. Using binary logistic regression, *cagA*+/ *homB*+ and *cagA*+/ *vacA*s1 genotypes were found to have the highest discriminatory capacity to

distinguish PUD from NUD in children, among the evaluated combinations of virulence factors<sup>[42]</sup>. Another study on pediatric strains showed that quadruple-positive strains (*vacA* s1/m1/*cagA*+/*babA2*+) had the highest discriminating value for detecting the severity of gastritis compared to other groups evaluated<sup>[17]</sup>. Interestingly, whereas *homB* was not associated with a severe finding on gastric histology when considered as an individual marker of the disease, a correlation between the *vacA* s2/m2/*cagA*-/*babA2*-/*homB*+ genotype and the presence of atrophic changes in Slovenian children was found<sup>[50]</sup>. Moreover, a study evaluating the prevalence and relevance of various *H. pylori* virulence factors in the pathogenesis of low-grade gastric MALT lymphoma was unable to identify correlations between any of the putative virulence genes and MALT lymphoma when evaluated individually. However, when using multiple correspondence analysis, patients infected with strains carrying *iceA1*, *sabA* "on" and *hopZ* "off" had 10-fold higher odds (OR = 10.3, 95% CI: 1.2-86.0) of developing MALT lymphoma than age-matched patients with gastritis<sup>[99]</sup>.

## CONCLUSION

*H. pylori* isolates show a high degree of geographic variability. It is thus possible that certain *H. pylori* genotypes are associated with a more severe clinical outcome in some regions, while presenting as virtually harmless variants in other studied populations. The observed discrepancies in several studies on *H. pylori* virulence genes may be due to various factors: different definitions or diagnoses of gastroduodenal disease, limitations of PCR and sequencing methods for detecting virulence genes (e.g., inadequate PCR primer design, disregarding frameshift mutations that could have a considerable influence on protein expression and/or function, and poor correlation of the genotypic methods with the actual expression profile of the protein), and inability to detect mixed infections with more than one strain at a time. Moreover, differences between East Asian and Western strains confirm the hypothesis that the degree of gastroduodenal pathology depends on complex relationships between host genetics, environmental factors and the presence, as well as combinations, of various *H. pylori* virulence genes. Although the importance of the majority of *H. pylori* virulence genes has not yet been uniformly clarified, knowledge on their role in pathogenesis, as well as disease outcome, has substantially improved in the last two decades. Careful monitoring and continuous refining of their roles will not only contribute to novel strategies for *H. pylori* vaccine development but also impact potential alternative therapies and facilitate the discovery of novel virulence genes. Although sequencing methods have dramatically improved over the years, enabling better and in-depth information on *H. pylori* genome structure, future studies should not only focus on these methods but also account for differences in protein expression profiles. Nevertheless, enriched knowledge on the pathogenicity of *H. pylori* virulence genes may be of clinical significance, since the detection of more virulent variants of strains, such as those with an increased number of CagA EPIYA-motifs, could be used to improve clinical prediction of the disease risk and identify those who need more intensive surveillance and eradication of the infection to prevent serious health-related consequences. In addition, focusing on a single virulence factor is probably too restrictive, since clear linkages between various virulence factors with different biological roles and significances exist, which may act synergistically to induce serious gastroduodenal pathology. Moreover, in the light of recent studies demonstrating that early exposure to *H. pylori* provides some protection against subsequent atopy and allergic conditions in childhood<sup>[100]</sup>, identification of reliable discriminative virulence factors of bacterial strains could be extremely helpful in the event that triaging of *H. pylori* infection is applied in the future.

## REFERENCES

- 1 Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of *Helicobacter pylori* infection worldwide: A systematic review of studies with national coverage. *Dig Dis Sci* 2014; **59**: 1698-1709 [PMID: 24563236 DOI: 10.1007/s10620-014-3063-0]
- 2 Kao CY, Sheu BS, Wu JJ. *Helicobacter pylori* infection: An overview of bacterial virulence factors and pathogenesis. *Biomed J* 2016; **39**: 14-23 [PMID: 27105595 DOI: 10.1016/j.bj.2015.06.002]
- 3 Whitmire JM, Merrell DS. *Helicobacter pylori* Genetic Polymorphisms in Gastric Disease Development. *Adv Exp Med Biol* 2019 [PMID: 31016629 DOI: 10.1007/5584\_2019\_365]
- 4 Kalali B, Mejias-Luque R, Javaheri A, Gerhard M. H. *pylori* virulence factors: Influence on immune system and pathology. *Mediators Inflamm* 2014; **2014**: 426309 [PMID: 24587595 DOI: 10.1155/2014/426309]
- 5 Yamaoka Y. Mechanisms of disease: *Helicobacter pylori* virulence factors. *Nat Rev Gastroenterol*

- Hepatology* 2010; **7**: 629-641 [PMID: 20938460 DOI: 10.1038/nrgastro.2010.154]
- 6 New Global Cancer Data: GLOBOCAN 2018; 2018 [cited 2019 Apr 14]. Available from: <https://www.uicc.org/new-global-cancer-data-globocan-2018>
  - 7 Kori M, Daugule I, Urbonas V. *Helicobacter pylori* and some aspects of gut microbiota in children. *Helicobacter* 2018; **23** Suppl 1: e12524 [PMID: 30203591 DOI: 10.1111/hel.12524]
  - 8 Razavi A, Bagheri N, Azadegan-Dehkordi F, Shirzad M, Rahimian G, Rafieian-Kopaei M, Shirzad H. Comparative Immune Response in Children and Adults with H. pylori Infection. *J Immunol Res* 2015; **2015**: 315957 [PMID: 26495322 DOI: 10.1155/2015/315957]
  - 9 Alm RA, Bina J, Andrews BM, Doig P, Hancock RE, Trust TJ. Comparative genomics of *Helicobacter pylori*: Analysis of the outer membrane protein families. *Infect Immun* 2000; **68**: 4155-4168 [PMID: 10858232 DOI: 10.1128/IAI.68.7.4155-4168.2000]
  - 10 Fujimoto S, Olaniyi Ojo O, Arnqvist A, Wu JY, Odenbreit S, Haas R, Graham DY, Yamaoka Y. *Helicobacter pylori* BabA expression, gastric mucosal injury, and clinical outcome. *Clin Gastroenterol Hepatol* 2007; **5**: 49-58 [PMID: 17157077 DOI: 10.1016/j.cgh.2006.09.015]
  - 11 Chang WL, Yeh YC, Sheu BS. The impacts of H. pylori virulence factors on the development of gastroduodenal diseases. *J Biomed Sci* 2018; **25**: 68 [PMID: 30205817 DOI: 10.1186/s12929-018-0466-9]
  - 12 Sheu SM, Sheu BS, Chiang WC, Kao CY, Wu HM, Yang HB, Wu JJ. H. pylori clinical isolates have diverse babAB genotype distributions over different topographic sites of stomach with correlation to clinical disease outcomes. *BMC Microbiol* 2012; **12**: 89 [PMID: 22646246 DOI: 10.1186/1471-2180-12-89]
  - 13 Chen MY, He CY, Meng X, Yuan Y. Association of *Helicobacter pylori* babA2 with peptic ulcer disease and gastric cancer. *World J Gastroenterol* 2013; **19**: 4242-4251 [PMID: 23864790 DOI: 10.3748/wjg.v19.i26.4242]
  - 14 Sheu BS, Odenbreit S, Hung KH, Liu CP, Sheu SM, Yang HB, Wu JJ. Interaction between host gastric Sialyl-Lewis X and H. pylori SabA enhances H. pylori density in patients lacking gastric Lewis B antigen. *Am J Gastroenterol* 2006; **101**: 36-44 [PMID: 16405531 DOI: 10.1111/j.1572-0241.2006.00358.x]
  - 15 Gerhard M, Lehn N, Neumayer N, Borén T, Rad R, Schepp W, Miehke S, Classen M, Prinz C. Clinical relevance of the *Helicobacter pylori* gene for blood-group antigen-binding adhesin. *Proc Natl Acad Sci U S A* 1999; **96**: 12778-12783 [PMID: 10535999 DOI: 10.1073/pnas.96.22.12778]
  - 16 Berthet E, Yahara K, Thorell K, Pascoe B, Meric G, Mikhail JM, Engstrand L, Enroth H, Burette A, Megraud F, Varon C, Atherton JC, Smith S, Wilkinson TS, Hitchings MD, Falush D, Sheppard SK. A GWAS on *Helicobacter pylori* strains points to genetic variants associated with gastric cancer risk. *BMC Biol* 2018; **16**: 84 [PMID: 30071832 DOI: 10.1186/s12915-018-0550-3]
  - 17 Homan M, Šterbenc A, Kocjan BJ, Luzar B, Zidar N, Orel R, Poljak M. Prevalence of the *Helicobacter pylori* babA2 gene and correlation with the degree of gastritis in infected Slovenian children. *Antonie Van Leeuwenhoek* 2014; **106**: 637-645 [PMID: 25055876 DOI: 10.1007/s10482-014-0234-0]
  - 18 Biernat MM, Gościński G, Iwańczak B. Prevalence of *Helicobacter pylori* cagA, vacA, iceA, babA2 genotypes in Polish children and adolescents with gastroduodenal disease. *Postępy Hig Med Dosw (Online)* 2014; **68**: 1015-1021 [PMID: 25228509 DOI: 10.5604/17322693.1118211]
  - 19 Podzorski RP, Podzorski DS, Wuerth A, Tolia V. Analysis of the vacA, cagA, cagE, iceA, and babA2 genes in *Helicobacter pylori* from sixty-one pediatric patients from the Midwestern United States. *Diagn Microbiol Infect Dis* 2003; **46**: 83-88 [PMID: 12812722 DOI: 10.1016/S0732-8893(03)00034-8]
  - 20 Talarico S, Gold BD, Fero J, Thompson DT, Guarner J, Czinn S, Salama NR. Pediatric *Helicobacter pylori* isolates display distinct gene coding capacities and virulence gene marker profiles. *J Clin Microbiol* 2009; **47**: 1680-1688 [PMID: 19386830 DOI: 10.1128/JCM.00273-09]
  - 21 Oleastro M, Gerhard M, Lopes AI, Ramalho P, Cabral J, Sousa Guerreiro A, Monteiro L. *Helicobacter pylori* virulence genotypes in Portuguese children and adults with gastroduodenal pathology. *Eur J Clin Microbiol Infect Dis* 2003; **22**: 85-91 [PMID: 12627281 DOI: 10.1007/s10096-002-0865-3]
  - 22 Oleastro M, Santos A, Cordeiro R, Nunes B, Mégraud F, Ménard A. Clinical relevance and diversity of two homologous genes encoding glycosyltransferases in *Helicobacter pylori*. *J Clin Microbiol* 2010; **48**: 2885-2891 [PMID: 20554820 DOI: 10.1128/JCM.00401-10]
  - 23 Garcia GT, Aranda KR, Gonçalves ME, Cardoso SR, Iriya K, Silva NP, Scaletsky IC. High prevalence of clarithromycin resistance and cagA, vacA, iceA2, and babA2 genotypes of *Helicobacter pylori* in Brazilian children. *J Clin Microbiol* 2010; **48**: 4266-4268 [PMID: 20826649 DOI: 10.1128/JCM.01034-10]
  - 24 Boyanova L, Yordanov D, Gergova G, Markovska R, Mitov I. Association of iceA and babA genotypes in *Helicobacter pylori* strains with patient and strain characteristics. *Antonie Van Leeuwenhoek* 2010; **98**: 343-350 [PMID: 20454856 DOI: 10.1007/s10482-010-9448-y]
  - 25 Ozbey G, Dogan Y, Demiroren K. Prevalence of *Helicobacter pylori* virulence genotypes among children in Eastern Turkey. *World J Gastroenterol* 2013; **19**: 6585-6589 [PMID: 24151385 DOI: 10.3748/wjg.v19.i39.6585]
  - 26 Dossumbekova A, Prinz C, Mages J, Lang R, Kusters JG, Van Vliet AH, Reindl W, Backert S, Saur D, Schmid RM, Rad R. *Helicobacter pylori* HopH (OipA) and bacterial pathogenicity: Genetic and functional genomic analysis of hopH gene polymorphisms. *J Infect Dis* 2006; **194**: 1346-1355 [PMID: 17054063 DOI: 10.1086/508426]
  - 27 Zambon CF, Navaglia F, Basso D, Rugge M, Plebani M. *Helicobacter pylori* babA2, cagA, and s1 vacA genes work synergistically in causing intestinal metaplasia. *J Clin Pathol* 2003; **56**: 287-291 [PMID: 12663641 DOI: 10.1136/jcp.56.4.287]
  - 28 Teymournejad O, Mobarez AM, Hassan ZM, Talebi Bezmin Abadi A. Binding of the *Helicobacter pylori* OipA causes apoptosis of host cells via modulation of Bax/Bcl-2 levels. *Sci Rep* 2017; **7**: 8036 [PMID: 28808292 DOI: 10.1038/s41598-017-08176-7]
  - 29 Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori* oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. *Gastroenterology* 2002; **123**: 414-424 [PMID: 12145793 DOI: 10.1053/gast.2002.34781]
  - 30 Braga LL, Oliveira MA, Gonçalves MH, Chaves FK, Benigno TG, Gomes AD, Silva CI, Anacleto C, Batista Sde A, Queiroz DM. CagA phosphorylation EPIYA-C motifs and the vacA i genotype in *Helicobacter pylori* strains of asymptomatic children from a high-risk gastric cancer area in northeastern Brazil. *Mem Inst Oswaldo Cruz* 2014; **109**: 1045-1049 [PMID: 25494468 DOI: 10.1590/0074-0276140279]
  - 31 Farzi N, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among *Helicobacter pylori* isolates from Iranian patients with different gastric diseases. *Infect Genet Evol* 2018; **60**: 26-34 [PMID: 29452293 DOI: 10.1016/j.meegid.2018.05.015]

- 10.1016/j.meegid.2018.02.017]
- 32 **Torres K**, Valderrama E, Sayegh M, Ramirez JL, Chiurillo MA. Study of the oipA genetic diversity and EPIYA motif patterns in cagA-positive *Helicobacter pylori* strains from Venezuelan patients with chronic gastritis. *Microb Pathog* 2014; **76**: 26-32 [PMID: 25223715 DOI: 10.1016/j.micpath.2014.09.006]
  - 33 **Markovska R**, Boyanova L, Yordanov D, Gergova G, Mitov I. *Helicobacter pylori* oipA genetic diversity and its associations with both disease and cagA, vacA s, m, and i alleles among Bulgarian patients. *Diagn Microbiol Infect Dis* 2011; **71**: 335-340 [PMID: 21937185 DOI: 10.1016/j.diagmicrobio.2011.08.008]
  - 34 **Schmidt HM**, Andres S, Nilsson C, Kovach Z, Kaakoush NO, Engstrand L, Goh KL, Fock KM, Forman D, Mitchell H. The cag PAI is intact and functional but HP0521 varies significantly in *Helicobacter pylori* isolates from Malaysia and Singapore. *Eur J Clin Microbiol Infect Dis* 2010; **29**: 439-451 [PMID: 20157752 DOI: 10.1007/s10096-010-0881-7]
  - 35 **Chiarini A**, Calà C, Bonura C, Gullo A, Giuliana G, Peralta S, D'Arpa F, Giammanco A. Prevalence of virulence-associated genotypes of *Helicobacter pylori* and correlation with severity of gastric pathology in patients from western Sicily, Italy. *Eur J Clin Microbiol Infect Dis* 2009; **28**: 437-446 [PMID: 18958508 DOI: 10.1007/s10096-008-0644-x]
  - 36 **Yamaoka Y**, Ojo O, Fujimoto S, Odenbreit S, Haas R, Gutierrez O, El-Zimaity HM, Reddy R, Arnqvist A, Graham DY. *Helicobacter pylori* outer membrane proteins and gastroduodenal disease. *Gut* 2006; **55**: 775-781 [PMID: 16322107 DOI: 10.1136/gut.2005.083014]
  - 37 **de Jonge R**, Pot RG, Loffeld RJ, van Vliet AH, Kuipers EJ, Kusters JG. The functional status of the *Helicobacter pylori* sabB adhesin gene as a putative marker for disease outcome. *Helicobacter* 2004; **9**: 158-164 [PMID: 15068418 DOI: 10.1111/j.1083-4389.2004.00213.x]
  - 38 **Ando T**, Peek RM, Pride D, Levine SM, Takata T, Lee YC, Kusugami K, van der Ende A, Kuipers EJ, Kusters JG, Blaser MJ. Polymorphisms of *Helicobacter pylori* HP0638 reflect geographic origin and correlate with cagA status. *J Clin Microbiol* 2002; **40**: 239-246 [PMID: 11773122 DOI: 10.1128/JCM.40.1.239-246.2002]
  - 39 **Leung WK**, Yu J, To KF, Go MY, Ma PK, Chan FK, Sung JJ. Apoptosis and proliferation in *Helicobacter pylori*-associated gastric intestinal metaplasia. *Aliment Pharmacol Ther* 2001; **15**: 1467-1472 [PMID: 11552920 DOI: 10.1046/j.1365-2036.2001.01057.x]
  - 40 **Liu J**, He C, Chen M, Wang Z, Xing C, Yuan Y. Association of presence/absence and on/off patterns of *Helicobacter pylori* oipA gene with peptic ulcer disease and gastric cancer risks: A meta-analysis. *BMC Infect Dis* 2013; **13**: 555 [PMID: 24256489 DOI: 10.1186/1471-2334-13-555]
  - 41 **Yamaoka Y**, Reddy R, Graham DY. *Helicobacter pylori* virulence factor genotypes in children in the United States: Clues about genotype and outcome relationships. *J Clin Microbiol* 2010; **48**: 2550-2551 [PMID: 20421443 DOI: 10.1128/JCM.00114-10]
  - 42 **Oleastro M**, Cordeiro R, Ferrand J, Nunes B, Lehours P, Carvalho-Oliveira I, Mendes AI, Penque D, Monteiro L, Mégraud F, Ménard A. Evaluation of the clinical significance of homB, a novel candidate marker of *Helicobacter pylori* strains associated with peptic ulcer disease. *J Infect Dis* 2008; **198**: 1379-1387 [PMID: 18811585 DOI: 10.1086/592166]
  - 43 **Oleastro M**, Cordeiro R, Yamaoka Y, Queiroz D, Mégraud F, Monteiro L, Ménard A. Disease association with two *Helicobacter pylori* duplicate outer membrane protein genes, homB and homA. *Gut Pathog* 2009; **1**: 12 [PMID: 19545429 DOI: 10.1186/1757-4749-1-12]
  - 44 **Kang J**, Jones KR, Jang S, Olsen CH, Yoo YJ, Merrell DS, Cha JH. The geographic origin of *Helicobacter pylori* influences the association of the homB gene with gastric cancer. *J Clin Microbiol* 2012; **50**: 1082-1085 [PMID: 22205793 DOI: 10.1128/JCM.06293-11]
  - 45 **Talebi Bezin Abadi A**, Rafiei A, Ajami A, Hosseini V, Taghvaei T, Jones KR, Merrell DS. *Helicobacter pylori* homB, but not cagA, is associated with gastric cancer in Iran. *J Clin Microbiol* 2011; **49**: 3191-3197 [PMID: 21734027 DOI: 10.1128/JCM.00947-11]
  - 46 **Oleastro M**, Cordeiro R, Ménard A, Yamaoka Y, Queiroz D, Mégraud F, Monteiro L. Allelic diversity and phylogeny of homB, a novel co-virulence marker of *Helicobacter pylori*. *BMC Microbiol* 2009; **9**: 248 [PMID: 19954539 DOI: 10.1186/1471-2180-9-248]
  - 47 **Jung SW**, Sugimoto M, Graham DY, Yamaoka Y. homB status of *Helicobacter pylori* as a novel marker to distinguish gastric cancer from duodenal ulcer. *J Clin Microbiol* 2009; **47**: 3241-3245 [PMID: 19710266 DOI: 10.1128/JCM.00293-09]
  - 48 **Hussein NR**. A study of *Helicobacter pylori* outer-membrane proteins (hom) A and B in Iraq and Turkey. *J Infect Public Health* 2011; **4**: 135-139 [PMID: 21843859 DOI: 10.1016/j.jiph.2011.03.004]
  - 49 **Oleastro M**, Monteiro L, Lehours P, Mégraud F, Ménard A. Identification of markers for *Helicobacter pylori* strains isolated from children with peptic ulcer disease by suppressive subtractive hybridization. *Infect Immun* 2006; **74**: 4064-4074 [PMID: 16790780 DOI: 10.1128/IAI.00123-06]
  - 50 **Šterbenc A**, Poljak M, Zidar N, Luzar B, Homan M. Prevalence of the *Helicobacter pylori* homA and homB genes and their correlation with histological parameters in children. *Microb Pathog* 2018; **125**: 26-32 [PMID: 30195645 DOI: 10.1016/j.micpath.2018.09.005]
  - 51 **Oleastro M**, Cordeiro R, Ménard A, Gomes JP. Allelic diversity among *Helicobacter pylori* outer membrane protein genes homB and homA generated by recombination. *J Bacteriol* 2010; **192**: 3961-3968 [PMID: 20525831 DOI: 10.1128/JB.00395-10]
  - 52 **Mahdavi J**, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. *Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation. *Science* 2002; **297**: 573-578 [PMID: 12142529 DOI: 10.1126/science.1069076]
  - 53 **Yamaoka Y**. Increasing evidence of the role of *Helicobacter pylori* SabA in the pathogenesis of gastroduodenal disease. *J Infect Dev Ctries* 2008; **2**: 174-181 [PMID: 19738347 DOI: 10.3855/jidc.259]
  - 54 **Yanai A**, Maeda S, Hikiba Y, Shibata W, Ohmae T, Hirata Y, Ogura K, Yoshida H, Omata M. Clinical relevance of *Helicobacter pylori* sabA genotype in Japanese clinical isolates. *J Gastroenterol Hepatol* 2007; **22**: 2228-2232 [PMID: 18031386 DOI: 10.1111/j.1440-1746.2007.04831.x]
  - 55 **Odenbreit S**, Swoboda K, Barwig I, Ruhl S, Borén T, Koletzko S, Haas R. Outer membrane protein expression profile in *Helicobacter pylori* clinical isolates. *Infect Immun* 2009; **77**: 3782-3790 [PMID: 19546190 DOI: 10.1128/IAI.00364-09]
  - 56 **Kato S**, Osaki T, Kamiya S, Zhang XS, Blaser MJ. *Helicobacter pylori* sabA gene is associated with iron deficiency anemia in childhood and adolescence. *PLoS One* 2017; **12**: e0184046 [PMID: 28854239 DOI: 10.1371/journal.pone.0184046]
  - 57 **Backert S**, Blaser MJ. The Role of CagA in the Gastric Biology of *Helicobacter pylori*. *Cancer Res* 2016;



- 76: 4028-4031 [PMID: 27655809 DOI: 10.1158/0008-5472.CAN-16-1680]
- 58 **Xia Y**, Yamaoka Y, Zhu Q, Matha I, Gao X. A comprehensive sequence and disease correlation analyses for the C-terminal region of CagA protein of *Helicobacter pylori*. *PLoS One* 2009; **4**: e7736 [PMID: 19893742 DOI: 10.1371/journal.pone.0007736]
- 59 **Jones KR**, Whitmire JM, Merrell DS. A Tale of Two Toxins: *Helicobacter Pylori* CagA and VacA Modulate Host Pathways that Impact Disease. *Front Microbiol* 2010; **1**: 115 [PMID: 21687723 DOI: 10.3389/fmicb.2010.00115]
- 60 **Olbermann P**, Josenhans C, Moodley Y, Uhr M, Stamer C, Vauterin M, Suerbaum S, Achtman M, Linz B. A global overview of the genetic and functional diversity in the *Helicobacter pylori* cag pathogenicity island. *PLoS Genet* 2010; **6**: e1001069 [PMID: 20808891 DOI: 10.1371/journal.pgen.1001069]
- 61 **Akeel M**, Shehata A, Elhafey A, Elmakki E, Aboshouk T, Ageely H, Mahfouz M. *Helicobacter pylori* vacA, cagA and iceA genotypes in dyspeptic patients from southwestern region, Saudi Arabia: Distribution and association with clinical outcomes and histopathological changes. *BMC Gastroenterol* 2019; **19**: 16 [PMID: 30683054 DOI: 10.1186/s12876-019-0934-z]
- 62 **Yamaoka Y**. Pathogenesis of *Helicobacter pylori*-Related Gastrointestinal Diseases from Molecular Epidemiological Studies. *Gastroenterol Res Pract* 2012; **2012**: 371503 [PMID: 22829807 DOI: 10.1155/2012/371503]
- 63 **Park JY**, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of *Helicobacter pylori* and CagA-Positive Infections and Global Variations in Gastric Cancer. *Toxins (Basel)* 2018; **10**: pii: E163 [PMID: 29671784 DOI: 10.3390/toxins10040163]
- 64 **Parsonnet J**, Friedman GD, Orentreich N, Vogelstein H. Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection. *Gut* 1997; **40**: 297-301 [PMID: 9135515 DOI: 10.1136/gut.40.3.297]
- 65 **Huang JQ**, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. *Gastroenterology* 2003; **125**: 1636-1644 [PMID: 14724815 DOI: 10.1053/j.gastro.2003.08.033]
- 66 **Shiota S**, Matsunari O, Watada M, Hanada K, Yamaoka Y. Systematic review and meta-analysis: The relationship between the *Helicobacter pylori* dupA gene and clinical outcomes. *Gut Pathog* 2010; **2**: 13 [PMID: 21040520 DOI: 10.1186/1757-4749-2-13]
- 67 **Matos JI**, de Sousa HA, Marcos-Pinto R, Dinis-Ribeiro M. *Helicobacter pylori* CagA and VacA genotypes and gastric phenotype: A meta-analysis. *Eur J Gastroenterol Hepatol* 2013; **25**: 1431-1441 [PMID: 23929249 DOI: 10.1097/MEG.0b013e328364b53e]
- 68 **Li Q**, Liu J, Gong Y, Yuan Y. Association of CagA EPIYA-D or EPIYA-C phosphorylation sites with peptic ulcer and gastric cancer risks: A meta-analysis. *Medicine (Baltimore)* 2017; **96**: e6620 [PMID: 28445260 DOI: 10.1097/MD.0000000000006620]
- 69 **Homan M**, Luzar B, Kocjan BJ, Orel R, Mocilnik T, Shrestha M, Kveder M, Poljak M. Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of *Helicobacter pylori* isolated from Slovenian children. *J Pediatr Gastroenterol Nutr* 2009; **49**: 289-296 [PMID: 19525870 DOI: 10.1097/MPG.0b013e31818f09f2]
- 70 **Rafeey M**, Ghotaslou R, Milani M, Farokhi N, Ghojzadeh M. Association between *Helicobacter pylori*, cagA, and vacA Status and Clinical Presentation in Iranian Children. *Iran J Pediatr* 2013; **23**: 551-556 [PMID: 24800016 DOI: 10.1089/bfm.2013.9982]
- 71 **Falsafi T**, Khani A, Mahjoub F, Asgarani E, Sotoudeh N. Analysis of vacA/cagA genotypes/status in *Helicobacter pylori* isolates from Iranian children and their association with clinical outcome. *Turk J Med Sci* 2015; **45**: 170-177 [PMID: 25790548 DOI: 10.3906/sag-1311-2]
- 72 **Saltik IN**, Demir H, Engin D, Ertunç OD, Akyön Y, Koçak N. The cagA status of *Helicobacter pylori* isolates from dyspeptic children in Turkey. *FEMS Immunol Med Microbiol* 2003; **36**: 147-149 [PMID: 12738384 DOI: 10.1016/S0928-8244(03)00024-5]
- 73 **Ortiz-Princz D**, Daoud G, Salgado-Sabel A, Cavazza ME. *Helicobacter pylori* infection in children: Should it be carefully assessed? *Eur Rev Med Pharmacol Sci* 2016; **20**: 1798-1813 [PMID: 27212173]
- 74 **Romo-González C**, Consuelo-Sánchez A, Camorlinga-Ponce M, Velázquez-Guadarrama N, García-Zúñiga M, Burguenio-Ferreira J, Coria-Jiménez R. Plasticity Region Genes jhp0940, jhp0945, jhp0947, and jhp0949 of *Helicobacter pylori* in Isolates from Mexican Children. *Helicobacter* 2015; **20**: 231-237 [PMID: 25735460 DOI: 10.1111/hel.12194]
- 75 **Ko JS**, Kim KM, Oh YL, Seo JK. cagA, vacA, and iceA genotypes of *Helicobacter pylori* in Korean children. *Pediatr Int* 2008; **50**: 628-631 [PMID: 19261108 DOI: 10.1111/j.1442-200X.2008.02641.x]
- 76 **Azuma T**, Kato S, Zhou W, Yamazaki S, Yamakawa A, Ohtani M, Fujiwara S, Minoura T, Inuma K, Kato T. Diversity of vacA and cagA genes of *Helicobacter pylori* in Japanese children. *Aliment Pharmacol Ther* 2004; **20** Suppl 1: 7-12 [PMID: 15298599 DOI: 10.1111/j.1365-2036.2004.01980.x]
- 77 **Sicinschi LA**, Correa P, Bravo LE, Peek RM, Wilson KT, Loh JT, Yezpe MC, Gold BD, Thompson DT, Cover TL, Schneider BG. Non-invasive genotyping of *Helicobacter pylori* cagA, vacA, and hopQ from asymptomatic children. *Helicobacter* 2012; **17**: 96-106 [PMID: 22404439 DOI: 10.1111/j.1523-5378.2011.00919.x]
- 78 **Zhang SH**, Xie Y, Li BM, Liu DS, Wan SH, Luo LJ, Xiao ZJ, Li H, Yi LJ, Zhou J, Zhu X. [Prevalence of *Helicobacter pylori* cagA, vacA, and iceA genotypes in children with gastroduodenal diseases]. *Zhongguo Dang Dai Er Ke Za Zhi* 2016; **18**: 618-624 [PMID: 27412545]
- 79 **Atherton JC**, Cao P, Peek RM, Tummuru MK, Blaser MJ, Cover TL. Mosaicism in vacuolating cytotoxin alleles of *Helicobacter pylori*. Association of specific vacA types with cytotoxin production and peptic ulceration. *J Biol Chem* 1995; **270**: 17771-17777 [PMID: 7629077 DOI: 10.1074/jbc.270.30.17771]
- 80 **Foegeding NJ**, Caston RR, McClain MS, Ohi MD, Cover TL. An Overview of *Helicobacter pylori* VacA Toxin Biology. *Toxins (Basel)* 2016; **8**: pii: E173 [PMID: 27271669 DOI: 10.3390/toxins8060173]
- 81 **McClain MS**, Beckett AC, Cover TL. *Helicobacter pylori* Vacuolating Toxin and Gastric Cancer. *Toxins (Basel)* 2017; **9**: pii: E316 [PMID: 29023421 DOI: 10.3390/toxins9100316]
- 82 **Calore F**, Gennet C, Casellato A, Rossato M, Codolo G, Esposti MD, Scorrano L, de Bernard M. Endosome-mitochondria juxtaposition during apoptosis induced by H. pylori VacA. *Cell Death Differ* 2010; **17**: 1707-1716 [PMID: 20431599 DOI: 10.1038/cdd.2010.42]
- 83 **Van Doorn LJ**, Figueiredo C, Mégraud F, Pena S, Midolo P, Queiroz DM, Carneiro F, Vanderborgh B, Pegado MD, Sanna R, De Boer W, Schneeberger PM, Correa P, Ng EK, Atherton J, Blaser MJ, Quint WG. Geographic distribution of vacA allelic types of *Helicobacter pylori*. *Gastroenterology* 1999; **116**: 823-830 [PMID: 10092304 DOI: 10.1016/S0016-5085(99)70065-X]
- 84 **Ferreira RM**, Machado JC, Letley D, Atherton JC, Pardo ML, Gonzalez CA, Carneiro F, Figueiredo C. A



- novel method for genotyping the *Helicobacter pylori* vacA intermediate region directly in gastric biopsy specimens. *J Clin Microbiol* 2012; **50**: 3983-3989 [PMID: 23035185 DOI: 10.1128/JCM.02087-12]
- 85 **Abdi E**, Latifi-Navid S, Zahri S, Yazdanbod A, Safaralizadeh R. *Helicobacter pylori* genotypes determine risk of non-cardia gastric cancer and intestinal- or diffuse-type GC in Ardabil: A very high-risk area in Northwestern Iran. *Microb Pathog* 2017; **107**: 287-292 [PMID: 28390977 DOI: 10.1016/j.micpath.2017.04.007]
- 86 **Liu X**, He B, Cho WC, Pan Y, Chen J, Ying H, Wang F, Lin K, Peng H, Wang S. A systematic review on the association between the *Helicobacter pylori* vacA i genotype and gastric disease. *FEBS Open Bio* 2016; **6**: 409-417 [PMID: 27419046 DOI: 10.1002/2211-5463.12046]
- 87 **Goncalves MH**, Silva CI, Braga-Neto MB, Fialho AB, Fialho AM, Queiroz DM, Braga LL. *Helicobacter pylori* virulence genes detected by string PCR in children from an urban community in northeastern Brazil. *J Clin Microbiol* 2013; **51**: 988-989 [PMID: 23254125 DOI: 10.1128/JCM.02583-12]
- 88 **Yamaoka Y**, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY. Relationship of vacA genotypes of *Helicobacter pylori* to cagA status, cytotoxin production, and clinical outcome. *Helicobacter* 1998; **3**: 241-253 [PMID: 9844065 DOI: 10.1046/j.1523-5378.1998.08056.x]
- 89 **Gold BD**, van Doorn LJ, Guarner J, Owens M, Pierce-Smith D, Song Q, Hutwagner L, Sherman PM, de Mola OL, Czinn SJ. Genotypic, clinical, and demographic characteristics of children infected with *Helicobacter pylori*. *J Clin Microbiol* 2001; **39**: 1348-1352 [PMID: 11283055 DOI: 10.1128/JCM.39.4.1348-1352.2001]
- 90 **Shiota S**, Nguyen LT, Murakami K, Kuroda A, Mizukami K, Okimoto T, Kodama M, Fujioka T, Yamaoka Y. Association of *Helicobacter pylori* dupA with the failure of primary eradication. *J Clin Gastroenterol* 2012; **46**: 297-301 [PMID: 22298090 DOI: 10.1097/MCG.0b013e318243201c]
- 91 **Hussein NR**. The association of dupA and *Helicobacter pylori*-related gastroduodenal diseases. *Eur J Clin Microbiol Infect Dis* 2010; **29**: 817-821 [PMID: 20419465 DOI: 10.1007/s10096-010-0933-z]
- 92 **Gomes LI**, Rocha GA, Rocha AM, Soares TF, Oliveira CA, Bittencourt PF, Queiroz DM. Lack of association between *Helicobacter pylori* infection with dupA-positive strains and gastroduodenal diseases in Brazilian patients. *Int J Med Microbiol* 2008; **298**: 223-230 [PMID: 17897881 DOI: 10.1016/j.ijmm.2007.05.006]
- 93 **Argent RH**, Burette A, Miendje Devy VY, Atherton JC. The presence of dupA in *Helicobacter pylori* is not significantly associated with duodenal ulceration in Belgium, South Africa, China, or North America. *Clin Infect Dis* 2007; **45**: 1204-1206 [PMID: 17918084 DOI: 10.1086/522177]
- 94 **Lu H**, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of *Helicobacter pylori*. *Gastroenterology* 2005; **128**: 833-848 [PMID: 15825067 DOI: 10.1053/j.gastro.2005.01.009]
- 95 **Schmidt HM**, Andres S, Kaakoush NO, Engstrand L, Eriksson L, Goh KL, Fock KM, Hilmi I, Dhamodaran S, Forman D, Mitchell H. The prevalence of the duodenal ulcer promoting gene (dupA) in *Helicobacter pylori* isolates varies by ethnic group and is not universally associated with disease development: a case-control study. *Gut Pathog* 2009; **1**: 5 [PMID: 19338650 DOI: 10.1186/1757-4749-1-5]
- 96 **Paredes-Osses E**, Sáez K, Sanhueza E, Hebel S, González C, Briceño C, García Cancino A. Association between cagA, vacAi, and dupA genes of *Helicobacter pylori* and gastroduodenal pathologies in Chilean patients. *Folia Microbiol (Praha)* 2017; **62**: 437-444 [PMID: 28283946 DOI: 10.1007/s12223-017-0514-y]
- 97 **Pereira WN**, Ferraz MA, Zabaglia LM, de Labio RW, Orcini WA, Bianchi Ximenez JP, Neto AC, Payão SL, Rasmussen LT. Association among *H. pylori* virulence markers dupA, cagA and vacA in Brazilian patients. *J Venom Anim Toxins Incl Trop Dis* 2014; **20**: 1 [PMID: 24456629 DOI: 10.1186/1678-9199-20-1]
- 98 **González CA**, Figueiredo C, Lic CB, Ferreira RM, Pardo ML, Ruiz Liso JM, Alonso P, Sala N, Capella G, Sanz-Anquela JM. *Helicobacter pylori* cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: A long-term follow-up in a high-risk area in Spain. *Am J Gastroenterol* 2011; **106**: 867-874 [PMID: 21285949 DOI: 10.1038/ajg.2011.1]
- 99 **Lehours P**, Ménard A, Dupouy S, Bergey B, Richy F, Zerbib F, Ruskoné-Fourmestreaux A, Delchier JC, Mégraud F. Evaluation of the association of nine *Helicobacter pylori* virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma. *Infect Immun* 2004; **72**: 880-888 [PMID: 14742532 DOI: 10.1128/IAI.72.2.880-888.2004]
- 100 **Taye B**, Enquselassie F, Tsegaye A, Medhin G, Davey G, Venn A. Is *Helicobacter Pylori* infection inversely associated with atopy? A systematic review and meta-analysis. *Clin Exp Allergy* 2015; **45**: 882-890 [PMID: 25207960 DOI: 10.1111/cea.12404]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

